Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Other financing activities (2018 - 2024)

Historic Other financing activities for Capricor Therapeutics (CAPR) over the last 13 years, with Q4 2024 value amounting to $2.3 million.

  • Capricor Therapeutics' Other financing activities rose 2331.03% to $2.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $9.8 million, marking a year-over-year increase of 3209.74%. This contributed to the annual value of $9.8 million for FY2024, which is 3209.74% up from last year.
  • Per Capricor Therapeutics' latest filing, its Other financing activities stood at $2.3 million for Q4 2024, which was up 2331.03% from $2.1 million recorded in Q3 2024.
  • Over the past 5 years, Capricor Therapeutics' Other financing activities peaked at $3.3 million during Q1 2024, and registered a low of $287807.0 during Q1 2020.
  • Its 5-year average for Other financing activities is $1.3 million, with a median of $1.1 million in 2022.
  • As far as peak fluctuations go, Capricor Therapeutics' Other financing activities surged by 46703.19% in 2020, and later soared by 112.86% in 2021.
  • Capricor Therapeutics' Other financing activities (Quarter) stood at $473745.0 in 2020, then skyrocketed by 64.68% to $780150.0 in 2021, then surged by 47.18% to $1.1 million in 2022, then soared by 62.14% to $1.9 million in 2023, then grew by 23.31% to $2.3 million in 2024.
  • Its Other financing activities stands at $2.3 million for Q4 2024, versus $2.1 million for Q3 2024 and $2.2 million for Q2 2024.